TUCSON, AZ--(Marketwire - June 23, 2009) - CDEX Inc. (OTCBB: CEXI) announces that the Company’s progress, response to the global economy, its two product lines, its recently filed 2QFY0910Q and other subjects are discussed by CEO Malcolm Philips in the “CEO Corner” of our website at www.cdexinc.com.
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.
Contact:
Malcolm Philips
Email Contact
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
